EDEmile Daraï

Emile Daraï

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Emile Daraï has a total of 223 co-authors. Here are the top co-authors by number of shared publications:

  • Roman Rouzier

    Surgery Department, Centre François Baclesse, 14000 Caen, France

    24 shared publications
  • Marcos Ballester

    Department of Obstetrics and Gynecology, Tenon Hospital, Assistance Publique des Hôpitaux de Paris, University Pierre et Marie Curie, Paris, France; Groupe de Recherche Clinique 6, Centre Expert En Endométriose, University Pierre et Marie Curie, Paris, France; Unité Médicale de Recherche S938, University Pierre et Marie Curie, Paris, France

    20 shared publications
  • Marcos Ballester

    Assistance publique-Hôpitaux de Paris, université Pierre-et-Marie-Curie Paris 6, hôpital Tenon, GRC6-UPMC : centre expert en endométriose (C3E), service de gynécologie-obstétrique et médecine de la reproduction, 75020 Paris, France; Université Pierre-et-Marie-Curie Paris 6, Inserm, UMR_S938, 75012 Paris, France

    14 shared publications
  • Marc Bazot

    Department of Radiology, University Pierre et Marie Curie, Paris, France; Groupe de Recherche Clinique 6, Centre Expert En Endométriose, University Pierre et Marie Curie, Paris, France

    9 shared publications
  • Charles Coutant

    Hôpital Tenon, Assistance Publique des Hôpitaux de Paris, CancerEst, Université Pierre et Marie Curie

    7 shared publications
  • Cyril Touboul

    Department of Gynecology-Obstetrics, Expert center in Gynecology-Oncology, Tenon Hospital, Assistance Publique des Hôpitaux de Paris (APHP), Sorbonne University, Paris, France

    6 shared publications

Latest Publications

  • Open Access

    Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery

    by Gilles Houvenaeghel, Jean-Marc Classe, Marie-Pierre Chauvet, Pierre-Emmanuel Colombo, Eva Jouve, Fabien Reyal, Emile Daraï, Roman Rouzier, Christelle Faure-Virelizier, Pierre Gimbergues, et al.

    Background: Despite early diagnosis, approximately 20% of patients with ER-positive and HER2-negative breast cancer (BC) will experience disease recurrence. Improved survival has been reported with adjuvant treatment combining cyclin-dependent kinase 4/6 inhibitors with endocrine therapy, in high-risk patients with ER-positive and HER2-negative BC, regardless of age. Older patients have higher rates of ER-positive/HER2-negative BC than younger patients. Methods: In this real-world data analysis, MonarchE and NataLEE high-risk patients accounted for 9.5% and 33% of patients undergoing upfront surgery, respectively. Significantly higher eligibility rates were observed in patients who underwent a mastectomy, >70 years and ≤40 years for adjuvant abemaciclib and ribociclib, and in patients >80 years for ribociclib. Results: Eligibility rates in patients ≤40 years and >80 years who underwent mastectomy were 27.8% and 24.7% for abemaciclib, respectively, and 56.6% and 65.2% for ribociclib, respectively. A higher discontinuation rate for abemaciclib was reported in patients aged ≥65 years and it can be assumed that discontinuation rates may increase in even older patients. Conclusions: If the results of the NataLEE trial translate into clinical practice, the number of patients potentially eligible for adjuvant CDK4/6 inhibitors may increase, especially in the elderly population.


  • Open Access

    Surgical peritoneal stress creates a pro-metastatic niche promoting resistance to apoptosis via IL-8

    by Jennifer Pasquier, Fabien Vidal, Jessica Hoarau-Véchot, Claire Bonneau, Emile Daraï, Cyril Touboul, Arash Rafii

    The mainstay of treatment of advanced ovarian cancer (AOC) involves chemotherapy, and debulking surgery. However, despite optimal surgical procedure and adjuvant chemotherapy, 60% of patients with AOC will relapse within 5 years. Most recurrences occur in the peritoneal cavity, suggesting the existence of occult sanctuaries where ovarian cancer cells (OCC) are protected. In murine models, surgical stress favors tumor growth; however, it has never been established that surgery may affect OCC sensitivity to subsequent chemotherapy. In this study, we investigated how the surgical stress could affect the chemosensitivity of OCC. To avoid bias due to tumor burden in peritoneal cavity and duration of surgery, we used peritoneal biopsies from patients without a malignancy at precise time points. During laparotomies, peritoneal biopsies at the incision site were performed at the time of incision (H0 sample) and 1 h after initiation of surgery (H1 sample). We evaluated the chemoresistance to Taxol (0–20 µM) induced by H0 or H1 incubation (24 h) in two ovarian cancer cell lines OVCAR3 and SKOV3 and a primary cancer cell lines derived in our laboratory. Our results indicate that stressed peritoneum overexpressed cytokines, resulting in OCC increased resistance to therapy. Among these cytokines, IL8 was responsible for the resistance to apoptosis through the AKT pathway activation. Chemoresistance in OCC persists through the establishment of an autocrine IL8 loop. Finally, in a cohort of 32 patients, we showed an impact of IL8 tumoral overexpression on chemosensitivity and survival outcomes with a significant association to earlier recurrence. Our study demonstrated that precision surgery where targeted treatment would be used in combination with surgery is essential to obtain better tumor control.


  • Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact

    by Gilles Houvenaeghel, Alexandre de Nonneville, Monique Cohen, Jean-Marc Classe, Fabien Reyal, Chafika Mazouni, Nicolas Chopin, Alejandra Martinez, Emile Daraï, Charles Coutant, et al.

    Tumour features associated with isolated invasive breast cancer (BC) ipsilateral local recurrence (ILR) after breast conservative treatment (BCT) and consequences on overall survival (OS) are still debated. Our objective was to investigate these points.


  • Magnetic Resonance Enterography to Assess Multifocal and Multicentric Bowel Endometriosis

    by Krystel Nyangoh Timoh, Zelda Stewart, Mikhael Benjoar, Selma Beldjord, Marcos Ballester, Marc Bazot, Isabelle Thomassin-Naggara, Emile Darai


  • Sentinel lymph node biopsy validation for large tumors

    by Gilles Houvenaeghel, Olivia Quilichini, Monique Cohen, Fabien Reyal, Jean-Marc Classe, Chafika Mazouni, Sylvie Giard, Nicolas Carrabin, Hélène Charitansky, Emile Darai, et al.

    Sentinel lymph node biopsy (SLNB) remains under discussion for large size tumors. The aim of this work has been to study the false negative rate (FNR) of SLNB for large tumors and predictive factors of false negative (FN).A study of a multicentric cohort, involved patients presenting N0 breast cancer with a SLNB eventually completed by complementary axillary lymph node dissection (cALND). The main criteria were the FNR and the predictive factors of FN.12.415 patients were included: 748 with tumors ≥30 mm, 1101 with tumors >20 and < 30 mm and 10.566 with tumors ≤20 mm, with a cALND respectively for 501 patients (67%), 523 (62.1%) and 2775 (26.3%). The FNR were respectively: 3.05% (IC95%: 1.3-4.8) for tumors ≥30 mm*, 3.5% (1.8-5.2) for tumors >20 and < 30 mm*, 1.8% (1-2.4) for tumors ≤20 mm (p < 0.05) (*Not significant). At multivariate analysis, SN number harvested ≤2 (OR:2.0, p = 0.023) and tumor size >20 and < 30 mm (OR:2.07, p = 0.017) were significant predictive factors of FN, without significant value for tumor size ≥30 mm (OR:1.83, p = 0.073).The FNR of SLNB was not higher amongst large size tumors compared to tumors of a smaller size. These results support the validation of SNLB for tumors up to 50 mm.


  • Endométriose profonde et fertilité

    by Jonathan Cohen, Emmanuelle Mathieu D’Argent, Lise Selleret, Jean-Marie Antoine, Nathalie Chabbert-Buffet, Sofiane Bendifallah, Marcos Ballester, Emile Darai


  • Arguments pour différencier les cancers du sein associés à la grossesse de ceux diagnostiqués dans le post-partum : expérience monocentrique du réseau cancer associé à la grossesse (CALG)

    by Anne-Sophie Boudy, Iptissem Naoura, Sonia Zilberman, Joseph Gligorov, Nathalie Chabbert-Buffet, Marcos Ballester, Lise Selleret, Emile Darai


  • Micro-RNA signature of lymphovascular space involvement in type 1 endometrial cancer

    by Geoffroy Canlorbe, Mathieu Castela, Sofiane Bendifallah, Zhe Wang, Marine Lefevre, Nathalie Chabbert-Buffet, Selim Aractingi, Emile Daraï, Céline Méhats, Marcos Ballester

    This was the first study to investigate the relative expression of microRNA in type 1 EC according to LVSI status. This microRNA expression profile may provide a basis for further study of the microRNA function in EC, and be used as a diagnostic tool for LVSI status.


  • Maternal and neonatal outcomes in women with colorectal endometriosis

    by A Thomin, J Belghiti, C David, O Marty, M Bornes, M Ballester, H Roman, E Daraï

    Objective: To evaluate delivery and neonatal outcomes in women with resected or in situ bowel endometriosis.Design: Retrospective cohort study.Setting: France.Population and sample: Analysis of 72 pregnancies from 67 women followed for colorectal endometriosis from 2001 to 2014 in six centres including two university expert centres for endometriosis.Methods: Univariate analysis of maternal and neonatal outcomes.Main outcome measures: Routes for delivery and rate of complications.Results: The colorectal surgery group comprised 41 women and the in situ colorectal group, 26 women. Overall, half of the women underwent caesarean section. A high incidence of postoperative complications (39%) was observed after caesarean section with no difference between the groups. Surgical difficulties at newborn extraction (22%) and postoperative complications (39%) occurred more often in women with anterior deep infiltrating endometriosis (respectively 63 versus 11%, P = 0.007 and 67% versus 26%, P = 0.046) independently of prior surgery for endometriosis. In the remaining half, vaginal delivery required an operative procedure in 28% of the women with a significant increase in postpartum complications compared with those who did not require a procedure (P = 0.001). Overall, the incidence of postpartum complications was lower after vaginal delivery (14%) than after caesarean section (39%) (P = 0.03).Conclusion: Pregnant women with colorectal endometriosis, irrespective of prior surgery, should be informed of the high risk of delivery by caesarean section. Vaginal delivery is preferrable in this setting because of the lower incidence of postpartum complications.Tweetable Due to the incidence of postpartum complications whatever the route of delivery, women should receive level III maternal care.


    • 21 April 2016
      • Vol. 68  (6) , 642-52

    Finding the balance between surgery and medically-assisted reproduction in women with deep infiltrating endometriosis.

    by Jonathan Cohen, Marcos Ballester, Lise Selleret, Emmanuelle Mathieu D'argent, Jean M Antoine, Nathalie Chabbert-Buffet, Emile Darai

    Deep infiltrating endometriosis (DIE) affects several anatomical locations including the bladder, torus uterinum, uterosacral ligament, rectovaginal septum and bowel. It is the most debilitating form of endometriosis and causes severe pain, digestive and urinary symptoms as well as infertility. Faced with an infertile woman suffering from DIE, the dilemma is whether to opt for first-line IVF treatment or for surgery. In the absence of high-level of evidence from randomized studies, several factors should be taken into account in the decision-making process. The main criterion is whether the patient wants in-vitro fertilization (IVF) treatment or not. Secondly, while previous reports have demonstrated the positive impact of surgery on pregnancy, they also underline the risk of severe complications requiring management in expert centers. Despite the availability of predictive models or scoring systems, the decision mainly boils down to the couple's characteristics. It seems logical to propose first-line IVF when spontaneous fertility is not possible due to associated male infertility or tubal obstruction; for women aged ≥35 years; or in women with diminished ovarian reserve. Conversely, first-line surgery could be the best option for women without these characteristics. However, this strategy is mainly based on low-level of evidence underlining the requiring of randomized trials.